Currently patients either have to watch and wait before they are considered eligible for surgery. There are no other pharmacological treatments in development for the treatment of VMT. ![]() In its Final Appraisal Determination, NICE for the first time also characterized metamorphopsia as a ‘severe and distressing’ symptom with its impact on the patient being comparable to a loss of two lines in visual acuity.Īs a result, NICE not only recommends full reimbursement of Jetrea for patients with VMT and FTMH, smaller or equal to 400 microns, it also recommends reimbursement for those VMT patients with early stage VMT symptoms including metamorphopsia. ![]() The NICE FAD confirms NICE’s earlier Appraisal Consultation Document (ACD), which initially recommended Jetrea as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present. The UK’s National Institute for Health and Care Excellence (NICE) has confirmed its Final Appraisal Determination (FAD) recommendation for ThromboGenics' Jetrea (ocriplasmin) which is an innovative new treatment and should be reimbursed within the National Health Service (NHS) in England and Wales.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |